NCT01586936已完成不适用
Special Survey of Production of Antibody Against Coagulation
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 9
- 试验地点
- 1
- 主要终点
- Antibody production against eptacog alpha
研究概览
简要总结
This study is conducted in Japan. The aim of this registry study is to observe the use of single dose and multi-dose use of eptacog alpha (NovoSeven®) and to compare short-term outcomes, including effectiveness, safety, quality of life and treatment satisfaction with the approved treatments.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Treated with eptacog alpha (NovoSeven®)
排除标准
- •Investigator decision to measure for antibody as unnecessary medical testing
研究组 & 干预措施
eptacog alpha users
干预措施: eptacog alfa (activated) (Drug)
结局指标
主要结局
Antibody production against eptacog alpha
时间窗: Up to 10 years
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of LY3209590 in Japanese Participants With Type 2 DiabetesDiabetes Mellitus, Type 2NCT03603704Eli Lilly and Company31
已完成
1 期
Safety of Recombinant Factor XIII (rFXIII) in Healthy Japanese VolunteersAcquired Bleeding DisorderCardiac Surgery Requiring Cardiopulmonary BypassHealthyNCT01153997Novo Nordisk A/S24
已完成
1 期
Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of ONO-4685 in Japanese and Caucasian Healthy Adult Male SubjectsHealthy VolunteersNCT04079062Ono Pharmaceutical Co. Ltd78
已完成
1 期
Safety, Tolerability and Pharmacokinetics of NN1731 in Healthy VolunteersCongenital Bleeding DisorderHealthyNCT00822185Novo Nordisk A/S32
已完成
3 期
Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese InfantsInfections, RotavirusRotavirus VaccinesNCT00480324GlaxoSmithKline765